Technology
Health
Biotechnology

BioXcel Therapeutics

$10.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.81 (8.07%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BTAI and other stocks, options, ETFs, and crypto commission-free!

About

BioXcel Therapeutics, Inc. Common Stock, also called BioXcel Therapeutics, is a clinical stage biopharmaceutical company focuses on drug development. Read More The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Employees
18
Headquarters
New Haven, Connecticut
Founded
2017
Market Cap
169.97M
Price-Earnings Ratio
Dividend Yield
Average Volume
66.22K
High Today
$10.99
Low Today
$9.89
Open Price
$9.89
Volume
19.50K
52 Week High
$14.79
52 Week Low
$2.41

Collections

Technology
Health
Biotechnology
Medical
Therapy
Biopharmaceutical
Cancer Prevention
Pharmaceutical

News

Seeking AlphaMay 12

BioXcel Therapeutics, Inc. CEO Vimal Mehta on Q1 2019 Results - Earnings Call Transcript

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2019 Earnings Conference Call May 7, 2019 8:30 AM ET Company Participants Brian Johnston - AVP-IR, The Ruth Group Vimal Mehta - Founder, CEO, President, Secretary & Director Richard Steinhart - CFO Vincent O'Neill - SVP & Chief Medical Officer Frank Yocca - Chief Scientific Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Company Sumant Kulkarni - Canaccord Genuity Operator Good day, everyone, and welcome to the BioXcel Therap...

66
NasdaqMay 9

BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference

NEW HAVEN, Conn., May 09, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI") (Nasdaq:BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the 2019 UBS Global Healthcare Conference, being held May 20-22, 2019 in New York, NY. BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. Details of the presentatio...

33
Yahoo FinanceMay 7

BioXcel Therapeutics Reports First Quarter 2019 Results and Provides Business Update

72

Earnings

-$0.55
-$0.43
-$0.31
-$0.19
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.